CPH is targeting US growth through M&A - Seeking a CEO
Next Investors Oct 25, 2021
Today Creso Pharma’s (ASX:CPH) announced the acquisition of a range of CBD brand and product assets that deliver anti-inflammatory relief to professional and amateur athletes suffering from chronic muscle and joint pain.
CPH expands its footprint with new product launch and entry into Eastern Europe
Finfeed Archived May 21, 2021
Creso Pharma (ASX: CPH) will enter the Polish animal health market after signing a Letter of Intent with Polvet Healthcare Teodorowski Spółka Jawna. It has also finalised the development of anibidiol® swine, a new and innovative hemp flour and oat bran based complementary feed product.
Bod Australia appoints leading executive as CFO
Finfeed Archived Apr 12, 2021
Cannabis centric healthcare company Bod Australia Limited (ASX: BDA) has announced the appointment of accomplished senior accounting and financial management executive Mr Alan Dworkin as Chief Financial Officer, effective 3rd May 2021.
CPH looks to expand its footprint as NY State reaches deal legalise recreational cannabis
Finfeed Archived Apr 06, 2021
Creso Pharma (ASX: CPH) has appointed a US Director of Business Development just as New York State has legalised recreational cannabis. New York State is expected to become one of the largest recreational markets in the US valued at US$4.2BN.
$18M will help CPH progress near-term revenue initiatives
Finfeed Archived Mar 26, 2021
Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.
Neurotech expands exclusive license to include all neurological disorders
Finfeed Archived Mar 02, 2021
Neurotech International Limited (ASX: NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy, ADHD, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue and Migraine.